biphasic insulin aspart + insulin aspart
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes
Conditions
Diabetes, Diabetes Mellitus, Type 2
Trial Timeline
Feb 1, 2006 → Aug 1, 2006
NCT ID
NCT00282451About biphasic insulin aspart + insulin aspart
biphasic insulin aspart + insulin aspart is a approved stage product being developed by Novo Nordisk for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00282451. Target conditions include Diabetes, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00282451 | Approved | Completed |
Competing Products
20 competing products in Diabetes